Design Therapeutics, Inc.
NASDAQ:DSGNBiotechnology
+$0.19 today
- Market cap
- $606.42M
- Beta
- 1.66
- P/E (TTM)
- -10.7
- EPS (TTM)
- -$1.13
Volume 0.32M
Average 0.74M
DSGN Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Design Therapeutics, Inc.NASDAQ: DSGN
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 6.6% from a year ago
Cash & equivalents stood at $12.77M at the end of Q1 FY2026, down 6.6% from a year earlier and down 24.2% from the prior quarter. Over 3 fiscal years it compounded at -14.0% a year.
Context
- Cash & equivalents amounted to 5.5% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -6.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 16.86M USD
- Year-over-year change
- -25.3%
- 4-year CAGR
- -51.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.86M | -25.3% |
| FY2024 | 2024-12-31 | 22.56M | +6.4% |
| FY2023 | 2023-12-31 | 21.2M | -20.0% |
| FY2022 | 2022-12-31 | 26.5M | -91.1% |
| FY2021 | 2021-12-31 | 298.57M | — |
Cash & Equivalents vs competitors
How DSGN compares with its peers on the latest reported figures
- DSGN's Mar 2026 cash & equivalents of $12.77M is the lowest of the 11 companies compared; the peer median is $297.02M.
- Its year-over-year change of -6.6% is the 9th highest of 11, against a peer median of +29.3%.
- Cash & equivalents amounts to 5.5% of total assets for DSGN, versus a peer median of 33.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.05B | +3.2% | +52.1% | 32.3% | |
| Jun 2026 | $676.11M | +39.4% | +73.1% | 68.0% | |
| Mar 2026 | $544.59M | +124.0% | +89.5% | 93.3% | |
| Mar 2026 | $464.45M | +92.8% | -6.1% | 14.6% | |
| Mar 2026 | $297.74M | +41.4% | -27.2% | 70.4% | |
| Sep 2026 | $296.3M | -12.4% | +10.4% | 10.2% | |
| Mar 2026 | $177.91M | +742.2% | +47.1% | 85.3% | |
| Mar 2026 | $155.66M | -43.4% | -9.5% | 35.1% | |
| Mar 2026 | $50.26M | +19.2% | +77.9% | 14.5% | |
| Mar 2026 | $42.15M | -3.4% | -30.7% | 27.0% | |
| Mar 2026 | $12.77M | -6.6% | -14.0% | 5.5% | |
| Peer median (excluding DSGN) | $297.02M | +29.3% | +28.8% | 33.7% | |
Competitors are the stored peer set for DSGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 298.57M | 26.5M | 21.2M | 22.56M | 16.86M |
| Short-term Investments | 85.5M | 303.89M | 260.6M | 222.91M | 202.99M |
| Net Receivables | 110K | 1.12M | 1.43M | 1.26M | 1.68M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 385.44M | 335.12M | 284.58M | 248.04M | 223.78M |
| Property, Plant & Equipment (Net) | 5.12M | 5.56M | 4.63M | 3.63M | 2.42M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 459K | 430K | 427K | 0 |
| Total Non-current Assets | 5.12M | 6.02M | 5.06M | 4.05M | 2.42M |
| Total Assets | 390.56M | 341.14M | 289.64M | 252.09M | 226.2M |
| Account Payables | 1.62M | 3.03M | 1.94M | 2.19M | 2.31M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.15M | 3.54M | 4.03M | 3.58M | 4.63M |
| Total Current Liabilities | 5.28M | 10.78M | 9.62M | 8.46M | 13.06M |
| Long-term Debt | 0 | 0 | 0 | 0 | 645K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 3.14M | 3.05M | 2.33M | 1.53M | 645K |
| Total Liabilities | 8.43M | 13.83M | 11.96M | 10M | 13.7M |
| Common Stock | 6K | 6K | 6K | 6K | 6K |
| Retained Earnings | (47.46M) | (110.76M) | (177.63M) | (227.21M) | (297.01M) |
| Accumulated OCI | (244K) | (3.36M) | 62K | 475K | 403K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 382.13M | 327.31M | 277.69M | 242.1M | 212.5M |
| Total Debt | 3.63M | 3.69M | 3.05M | 2.33M | 1.54M |
| Net Debt | (294.94M) | (22.81M) | (18.15M) | (20.23M) | (15.32M) |
Design Therapeutics, Inc.
NASDAQ:DSGN
Intrinsic Alpha fair value
Locked
Current Price
$9.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.